Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry.
Michele MillesimoEdoardo EliaGiorgio MarengoOvidio De FilippoSergio Raposeiras-RoubinWojciech WańhaEmad Abu-AssiTim KinnairdAlbert Ariza-SoléChristoph LiebetrauSergio Manzano-FernándezMario IannacconeJose Paulo Simao HenriquesChristian TemplinStephen B WiltonLazar VelickiIoanna XanthopoulouLuis CorreiaEnrico CerratoAndrea RognoniIván Nuñez-GilXiantao SongTetsuma KawajiGiorgio QuadriZenon HuczekRafael Cobas PazJosé Ramón González JuanateyShao-Ping NieMasa-Aki KawashiriAlberto Dominguez-RodriguezFederico ConrottoFabrizio D'AscenzoGaetano Maria De FerrariPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
In a large cohort of ACS patients, one in three patients was eligible for either a prolonged DAPT with ticagrelor 60 mg and low-dose aspirin or a dual pathway inhibition approach with rivaroxaban 2.5 mg and low-dose aspirin.
Keyphrases
- low dose
- acute coronary syndrome
- end stage renal disease
- antiplatelet therapy
- newly diagnosed
- chronic kidney disease
- percutaneous coronary intervention
- high dose
- peritoneal dialysis
- atrial fibrillation
- type diabetes
- venous thromboembolism
- pulmonary embolism
- cardiovascular events
- cross sectional
- st elevation myocardial infarction